Search

Your search keyword '"CHU Bordeaux [Bordeaux]-Université de Bordeaux (UB)"' showing total 3 results
Start Over Author "CHU Bordeaux [Bordeaux]-Université de Bordeaux (UB)"
3 results on '"CHU Bordeaux [Bordeaux]-Université de Bordeaux (UB)"'

1. The adherence questionnaires in chronic inflammatory rheumatic diseases and their psychometric properties: A systematic literature review

Author

Anna Molto, Matthieu Lavielle, Maxime Dougados, René-Marc Flipo, Laure Gossec, Alain Saraux, Antsa Rakotozafiarison, Déborah Puyraimond-Zemmour, Christophe Richez, Xavier Romand, Gestionnaire, HAL Sorbonne Université 5, Service de Rhumatologie [CHU Pitié Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de Rhumatologie [CHU de Grenoble], Hôpital Sud de Grenoble, Translational microbial Evolution and Engineering (TIMC-TrEE), Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 (TIMC ), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), Chercheur indépendant, Service de rhumatologie[Lille], Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département de Rhumatologie, Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux], CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Bordeaux [Bordeaux]-Université de Bordeaux (UB), and Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
rheumatoid arthritis, medicine.medical_specialty, Psychometrics, Inflammatory arthritis, compliance, Medication Adherence, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Rheumatic Diseases, Surveys and Questionnaires, medicine, Humans, 030212 general & internal medicine, Intensive care medicine, ComputingMilieux_MISCELLANEOUS, inflammatory arthritis, 030203 arthritis & rheumatology, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, patient adherence, business.industry, questionnaires, spondyloarthritis, medicine.disease, 3. Good health, Systematic review, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Rheumatoid arthritis, Antirheumatic Agents, Chronic Disease, business
Abstract

International audience

Published
2021

2. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge

Author

Philippe Halfon, Patrick Blanco, Marie Kostine, Estibaliz Lazaro, Frédérique Retornaz, Caroline Charpin, Noémie Jourde-Chiche, Christophe Richez, Denis Arniaud, Laurent Chiche, C. Stavris, Département de Rhumatologie, CHU Bordeaux [Bordeaux]-Université de Bordeaux (UB), Hôpital Européen de Marseille (HEM), Hôpital du Haut-L'Evêque, Hôpital Européen [Fondation Ambroise Paré - Marseille], Hôpital Saint-Joseph [Marseille], Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Vascular research center of Marseille (VRCM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux], and Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Oncology, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Antineoplastic Agents, Autoimmunity, medicine.disease_cause, Autoimmune Diseases, 03 medical and health sciences, 0302 clinical medicine, Cancer immunotherapy, Neoplasms, Internal medicine, Internal Medicine, medicine, Humans, 030212 general & internal medicine, Enzyme Inhibitors, Adverse effect, Cancer, business.industry, Melanoma, Gastroenterology, Antibodies, Monoclonal, Cell Cycle Checkpoints, Immunotherapy, medicine.disease, 3. Good health, 030220 oncology & carcinogenesis, Immunology, Adenocarcinoma, Opportunistic, business, Adjuvant, Checkpoint inhibitors
Abstract

International audience; With "checkpoint inhibitors" targeting PD1/PD-1-ligands or CTLA-4/CD28 pathways, immunotherapy has profoundly modified therapeutic strategies in oncology. First approved in refractory metastatic neoplasms (melanoma and lung adenocarcinoma), it is now being tested broadly in other cancers and/or as adjuvant treatment. For a significant proportion of patients, immunotherapy is responsible for "immunological" events, identified as Immune-Related Adverse Events (irAEs). Owing to the increasing number of prescriptions, identification and management of specific immunological side effects is crucial and requires close collaboration between oncologists and internists and/or other organ specialists. Within irAEs, we propose to individualize the induced autoimmunity by the term "Opportunistic Autoimmunity Secondary to Cancer Immunotherapy" (OASI). The aims of this article are (1) to present the different available checkpoint inhibitors and the OASIs reported with these treatments and (2) to propose practical recommendations for diagnosis, pre-therapeutic assessment and management of OASIs. The need for predictive biomarkers of OASIs occurrence will also be discussed.

Published
2017

3. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort

Author

Thierry Schaeverbeke, Isabelle Logeart, Sabrina Dadoun, Bernard Combe, J.-P. Daurès, M. C. Belkacemi, Maxime Dougados, Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Pfizer Ltd France, Pfizer, Département de Rhumatologie, CHU Bordeaux [Bordeaux]-Université de Bordeaux (UB), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Service de rhumatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Génétique Moléculaire de Montpellier ( IGMM ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Montpellier ( UM ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Lapeyronie, Pfizer SAS, Département de Rhumatologie ( BORDEAUX - Rhumato ), Université de Bordeaux ( UB ) -CHU Bordeaux [Bordeaux], Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 ( AIDMP ), Université Montpellier 1 ( UM1 ) -Université de Montpellier ( UM ), CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - IURC, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Adult, Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Immunology, Blood Sedimentation, Logistic regression, Peptides, Cyclic, General Biochemistry, Genetics and Molecular Biology, Arthritis, Rheumatoid, Cohort Studies, Disease activity, symbols.namesake, Rheumatology, Internal medicine, medicine, Humans, Immunology and Allergy, Longitudinal Studies, Prospective Studies, Fisher's exact test, [ SDV ] Life Sciences [q-bio], Tumor Necrosis Factor-alpha, business.industry, Remission Induction, Middle Aged, Prognosis, medicine.disease, Connective tissue disease, 3. Good health, Surgery, Logistic Models, Methotrexate, Treatment Outcome, Antirheumatic Agents, Rheumatoid arthritis, Multivariate Analysis, Disease remission, Cohort, Disease Progression, symbols, Female, Outcomes research, business
Abstract

International audience; OBJECTIVE: To investigate if patients with early RA with persistent moderate disease activity during the first year after diagnosis have a worse 3-5 year outcome than those who achieve sustained clinical remission within the first year, in a daily life setting. METHODS: The ESPOIR cohort included patients with early arthritis of 3.2 and ≤5.1) at both the 6- and 12-month visits, with those who were in sustained DAS28 remission. The primary outcome was radiographic progression at the 36-month visit. Secondary endpoints were clinical remission (DAS28 score, Simplified Disease Activity Index, ACR/EULAR criteria), Health Assessment Questionnaire-Disability Index (HAQ-DI) and number of missed workdays at months 36 and 60. A Fisher exact test was used to compare categorical variables, and the Kruskal-Wallis test for quantitative variables. Logistic regression analysis was used to determine predictors of outcome. RESULTS: Patients were aged 48.1±12.5 years and their duration of symptoms was 103.2±52.1 days. Mean baseline DAS28 was 5.1±1.3. Persistent moderate disease activity (107 patients) rather than sustained remission (155 patients) during the first year was associated with increased radiographic disease progression at 3 years (OR=1.99 (95% CI 1.01 to 3.79)), increased HAQ-DI at 3 and 5 years (5.23 (2.81 to 9.73) and 4.10 (2.16 to 7.80), respectively), a 7-11 times smaller chance of achieving clinical remission and a five times greater number of missed workdays. CONCLUSIONS: Patients with early RA with persistent moderate disease activity during the first year had a worse outcome than patients who achieved sustained clinical remission. Persistent moderate disease activity affects long-term structure, remission rate and functional and work disability. Such patients may benefit from intensive treatment.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results